Request for Review: Autoimmune Hepatitis Case Definition

On behalf of the Brighton Collaboration Autoimmune Hepatitis Case Definition Working Group, please find below a manuscript on “Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data”.

It has been developed on an expedited basis as autoimmune hepatitis is an adverse event of special interest. There have been reports of autoimmune hepatitis developing following COVID-19 infection, including in unvaccinated patients.

The Working Group has members with significant clinical (adult and paediatric hepatologists with expertise in autoimmune hepatitis), vaccine safety, pharmacovigilance, and vaccine regulatory expertise from regulatory bodies, public health authorities, academia, and consulting from high and low- and middle-income countries.

The draft CD has undergone external review, including from Ethiopian, Malawian, Ugandan and Chilean investigators and the useful feedback received was discussed and incorporated in the document.

Please share your feedback by end of day Oct 16, 2023, if feasible.

Thank you

Best regards

Dr Sonali Kochhar and Prof John M. Vierling

Dr Sonali Kochhar, MD

Clinical Associate Professor

Department of Global Health

University of Washington, Seattle


John M. Vierling, MD, FACP, FAASLD. AGAF
Professor of Medicine and Surgery

Chief of Hepatology

Director of Baylor Liver Health

Director of Advanced Liver Therapies

Section of Gastroenterology and Hepatology

Margaret M. and Albert B. Alkek Department of Medicine
Baylor College of Medicine

Division of Abdominal Transplantation

Michael E. DeBakey Department of Surgery


Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab